As Japan gears up for its next drug pricing reform in April 2020, Shoji Kono, director of the National Federation…
HOME > ORGANIZATION
ORGANIZATION
- 7 EFPIA Companies Revised R&D Strategies after April Pricing Overhaul: Survey
November 9, 2018
- Wrong Policies Could Drive Investments Out of Japan amid China’s Rise, PhRMA Int’l Advocacy Chief Warns
November 6, 2018
- Japan, US, Europe Trade Groups Stress Importance of Drug Discovery, Call for “Angel Cycle”
November 5, 2018
- Limit CEA Application to Premium-Given Drugs with Big Sales: EFPIA Japan Officials
October 29, 2018
- EFPIA Japan Chief Eyes New Funding Model for Innovative but Pricey Therapies
October 26, 2018
- Japan Wholesaler Chief Suzuki Becomes IFPW Chairman
October 16, 2018
- Asian Consortium for Natural Substance-Based Drug Discovery to Leverage Asian Natural Resources, Japanese Technologies
October 15, 2018
- Japan Drug Industry Vows Further Efforts in Academic Collaboration after Honjo’s Nobel Prize
October 3, 2018
- Generic Use Rate at 72.2% in April-June: JGA
October 1, 2018
- October 2019 “Only Option” for Drug Price Revision Tied to Sales Tax Hike: New FPMAJ Chief
September 25, 2018
- 19 Companies Join JPMA Task Force on Quality Evaluation of Nucleic Acid Therapeutics
September 18, 2018
- Think Tank Led by Ex-Pfizer Japan Chief to Compile Proposal on “100-Year Life” by Year-End
September 5, 2018
- Bayer Yakuhin Chief Prinz Named Vice Chairman of EFPIA Japan
September 3, 2018
- Ex-Pfizer Japan Chief Umeda to Now Helm Advocacy Group
August 29, 2018
- Over Half of Companies Control Supply of Off-Label Information: Ihoken Survey
August 27, 2018
- Regulatory Science Society Says “No” to Off-Label Info Supply by Drug Reps Conditionally OK’ed in Draft MHLW GLs
August 24, 2018
- Drug Wholesalers Post Virtually Flat Sales in FY2017: JPWA
August 10, 2018
- Total No. of Sales Reps Shrinks for 4 Years in a Row at 62,433: Survey
July 27, 2018
- Generic Use Rate at 74.1% in January-March: JGA
July 4, 2018
- Yokokura Wins 4th Term to Lead Japan Medical Association
June 25, 2018
ページ
Pharmaceutical sales per rep in Japan, a yardstick for “productivity” at drug makers, reached a record 172 million yen in FY2018, up 20 million yen from five years ago, as companies continue ramping up their job-shedding drive in a bid…
An adult man who completed the administration of an investigational drug in a Japan PI study conducted by Eisai has died. Whether there was a causal relationship between the drug and the subject’s death remains unclear at the present time,…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Jascha Heifetz, widely regarded as one of the greatest violinists of all time, was once stopped, on 57th Street in Manhattan, by a pedestrian asking, “Could you tell me how to get to Carnegie Hall?” Heifetz pondered the question for…